Navigation Links
Silence Therapeutics Issued New U.S. Patent Covering Fundamental RNA Interference Technology Currently in Several Clinical Trials
Date:2/23/2011

tual property news, Silence also announces the issuance of United States patent 7,893,243, titled "Composition and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases," by the United States Patent and Trademark Office (USPTO).  This issued patent is broadly directed to a double stranded, double blunt ended siRNA sequence against the validated cancer target vascular endothelial growth factor (VEGF).  VEGF has been demonstrated to play an important role in the underlying causes of various cancers including abnormal angiogenesis and uncontrolled cell division.  The active pharmaceutical ingredient covered by the issued patent is a potent 25mer siRNA, with or without chemical modification, further demonstrating Silence's continued ability to secure meaningful intellectual property protection for its portfolio of 25mer sequences.  

Silence Therapeutics is executing a proactive strategy to continue to build and strengthen a global, diverse and competitive intellectual property portfolio that provides the Company and its partners with a strong proprietary position in the RNAi therapeutics space.  The Company believes that it will continue to make significant progress in these efforts as it expects additional RNAi patents to be issued in Japan, the United States and Europe during 2011.  At present, Silence's global patent portfolio contains issued patents and pending applications covering strategic areas of RNAi therapeutic development including multiple proprietary siRNA delivery technologies, potent siRNA sequences specific for high-value disease targets and key RNAi sequence and chemical modifications.

Notes for editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and deli
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Silence Therapeutics Provides Year-end Update
2. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
3. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
4. Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
5. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
6. Silence Therapeutics Announces Board Changes
7. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
8. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
9. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
10. Cornerstone Therapeutics to Host Fourth Quarter and Full Year 2010 Conference Call
11. Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses on ... the United States . Reimbursement analysis ... Thorough product analyses for more than 73 SMBG meters ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 ... Pharmaceuticals, Inc. today announced that the Committee for Medicinal ... Agency (EMA) has adopted a positive opinion for the ... of adult men with Peyronie,s disease with a palpable ... at the start of therapy. The use ...
(Date:12/22/2014)... , Dec. 22, 2014  Relmada Therapeutics, Inc. ... for the treatment of chronic pain, announced today ... dosed in a pharmacokinetic and pharmacodynamic study with ... neuropathic pain. Racemic methadone is a ... pain states and substitution therapy in opioid addiction.  ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... 2011 Styron, the global materials company and ... addition to its EMERGE™ Advanced Resins family in ... Resin is a polycarbonate blend with superior ... housing applications. (Logo: http://photos.prnewswire.com/prnh/20110809/CL49820LOGO) ...
... Technologies LLC, manufacturer of Active ... program at The Ohio State University through an initial $100,000+ ... endeavor will examine the importance and effects of specific products, ... The dramatic rise in bed bug infestations throughout the country ...
Cached Medicine Technology:Styron Introduces Chemical Resistance Blends for Medical Housings 2Allergy Technologies LLC Provides Over $100,000 in a Research Grant to The Ohio State University for the Study of Bed Bugs 2
(Date:12/22/2014)... 2014 Explorys, the leader in big ... leadership team: Greg Yarrington as Vice President of Operations, ... Wells as Vice President of Solutions. These new leaders ... jobs in 2015 to support client demand for the ... offerings, and growth of its partner network. , ...
(Date:12/22/2014)... 2014 Pasadena sleep apnea ... sleep apnea. Drowsy drivers are 15 times more likely ... well-rested, and some experts believe that sleep-deprived drivers may ... drivers. Unfortunately, millions of Americans may be sleep-deprived without ... Sleep Medicine, about 18 million Americans have sleep apnea, ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Christmas is days ... has a fast and easy solution that will please: the ... can be purchased from from $25 up to $350," says ... 100% customer satisfaction and a wide array of skin care ... fees and no expiration dates. , Gift delivery past ...
(Date:12/22/2014)... Washington, DC (PRWEB) December 22, 2014 ... Nursing Leadership Conference, next month in San ... strategies to address dynamics that often stand in ... authority, and competition. , This premier faculty ... Center for Transformational Leadership, whose mission is to ...
(Date:12/21/2014)... 2014 BellasDress.com offers a wide range ... Today, it announces its BellasDress Christmas Sale , ... online store. , BellasDress is a famous online supplier ... fans through a series of promotions. The dress experts ... , “We are proud of offering high quality ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:BellasDress.com Announces its BellasDress Christmas Sale 2
... LYMAN, S.C., Sept. 11 Southern Home Medical,Equipment, Inc. ... the month of August 2008 compared to July 2008., ... stated, "On the heels of,reporting record sales in the ... on a path of strong sales momentum. Encore Medical ...
... against women in a family also has serious consequences ... sling Monemi from Uppsala University has studied women and ... other things, that children whose mothers are exposed to ... other children. , Kajsa sling Monemi, paediatrician, the ...
... - For Non-US Healthcare Media, - Global ... Improved Survival Outcomes With Vetmedin(R) (pimobendan), Veterinarians and ... promise of an extended happy life together for millions ... that dogs,suffering from the most common type of heart ...
... Residents to Eat Right, Move More ... and Milk Their Diets, BOSTON, Sept. 11 ... fad diets -- which seem to go in and out of,fashion like shoulder ... -- including 51 percent of Massachusetts,residents -- remain overweight or obese., A ...
... 11 Oculus Innovative,Sciences, Inc. (Nasdaq: OCLS ), ... of products based upon the Microcyn(R),Technology platform, today announced ... exclusive interview on WallSt.net,s 3-Minute Press Show., The ... the,significance of the company,s latest press release., ...
... Plastic surgeon offers the surprise scoop, NEW ... time and an,active lifestyle can impact a person,s ... million Americans turned to cosmetic procedures last,year to ... Shirley Madhere, M.D., says you can improve your ...
Cached Medicine News:Health News:Southern Home Medical Announces Revenues Up 172% for the Month of August 2Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 2Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 3Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 4Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:[video] Hojabr Alimi, CEO of Oculus Innovative Sciences, Inc. Discusses Reduction of Planned Expenses on WallSt.net's 3-Minute Press Show 2Health News:Insider Secrets for Beautiful Skin 2
... RELISA ENA Multiparameter Kit is ... for six of the most ... a unique quality control system. ... Check) well in each strip ...
... RELISA ENA assays were designed with the ... clinician in the diagnosis of autoimmune disease. ... disease and 1,000 normal individuals were tested ... Test System. Immuno Concepts compared the results ...
... functional human C1q coated in the solid phase ... stage, CIC in the diluted patient samples and ... into the C1q coated assay wells. After incubation, ... and a ready to use conjugate (goat anti-human ...
... CIC are formed as a host ... cleared by phagocytosis. If not cleared, CIC ... inflammatory response. CIC are increased in Systemic ... may be involved in other autoimmune disorders ...
Medicine Products: